Loading...
XNASADVM
Market cap99mUSD
Dec 27, Last price  
4.80USD
1D
-4.38%
1Q
-30.84%
Jan 2017
65.52%
IPO
-80.92%
Name

Adverum Biotechnologies Inc

Chart & Performance

D1W1MN
XNAS:ADVM chart
P/E
—
P/S
27.74
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
-30.32%
Rev. gr., 5y
17.43%
Revenues
4m
30,000480,000572,0002,319,0001,455,0001,849,0001,612,000250,00007,500,00003,600,000
Net income
-117m
L-24.18%
-1,811,000-5,276,000-25,404,000-47,453,000-113,747,000-56,147,000-72,627,000-64,486,000-117,507,000-145,540,000-154,536,000-117,165,000
CFO
-91m
L-15.90%
-1,267,000-2,175,000-5,648,000-35,338,000-38,366,000-45,421,000-53,964,000-49,170,000-79,291,000-107,831,000-108,091,000-90,902,000
Earnings
Mar 17, 2025

Profile

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
URL
https://adverum.com/
IPO date
Jul 31, 2014
Employees
123
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,600
 
7,500
 
Cost of revenue
133,235
163,663
158,267
Unusual Expense (Income)
NOPBT
(129,635)
(163,663)
(150,767)
NOPBT Margin
Operating Taxes
(1,078)
74
4,408
Tax Rate
NOPAT
(128,557)
(163,737)
(155,175)
Net income
(117,165)
-24.18%
(154,536)
6.18%
(145,540)
23.86%
Dividends
Dividend yield
Proceeds from repurchase of equity
489
3
2,637
BB yield
-6.44%
-0.05%
-15.28%
Debt
Debt current
20,818
13,241
1,886
Long-term debt
139,663
200,363
204,102
Deferred revenue
Other long-term liabilities
1,047
1,114
Net debt
61,979
25,512
(102,472)
Cash flow
Cash from operating activities
(90,902)
(108,091)
(107,831)
CAPEX
(808)
(11,816)
(15,123)
Cash from investing activities
96,875
141,720
78,709
Cash from financing activities
69
607
2,397
FCF
(90,065)
(158,538)
(227,134)
Balance
Cash
96,526
185,589
305,188
Long term investments
1,976
2,503
3,272
Excess cash
98,322
188,092
308,085
Stockholders' equity
(920,240)
(804,133)
(648,780)
Invested Capital
1,095,241
1,093,246
1,067,755
ROIC
ROCE
EV
Common stock shares outstanding
10,082
9,925
9,804
Price
0.75
29.91%
0.58
-67.07%
1.76
-83.76%
Market cap
7,590
31.96%
5,752
-66.67%
17,255
-81.31%
EV
69,569
31,264
(85,217)
EBITDA
(123,991)
(157,135)
(146,122)
EV/EBITDA
0.58
Interest
2,673
Interest/NOPBT